乳腺癌中的抗体-药物结合物:当前的证据和未来的方向
Ning Li1, Lu Yang2,3, Zixuan Zhao1
1Department of Breast Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Experimental hematology & oncology
|March 21, 2025
概括
抗体-药物合物 (ADC) 正在彻底改变癌症治疗,其中四种已被批准用于乳腺癌. 本综述详细介绍了ADC的设计,进展以及改善抗瘤药物开发的未来方向.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
背景情况:
- 抗体-药物合物 (ADC) 代表了抗瘤疗法的重大进步,改变了各种癌症的治疗模式.
- 一些抗癌药物,包括trastuzumab emtansine (T-DM1),trastuzumab deruxtecan (T-DXd),sacituzumab govitecan (SG) 和datopotamab deruxtecan (Dato-DXd),已被FDA批准用于治疗乳腺癌.
- SKB264得到了中国NMPA的批准,突出显示了ADC开发的全球进展.
研究的目的:
- 提供关于抗体-药物合物 (ADC) 设计原则和最近进展的全面概述,专门用于乳腺癌治疗.
- 讨论当前的挑战,包括获得的耐药性,与治疗相关的毒性和生物标志物识别.
- 探索未来的方向和新的下一代ADC开发.
主要方法:
- 对乳腺癌中抗体-药物联合体 (ADCs) 现有研究的文献综述.
- 分析已批准的ADC,晚期临床试验结果和正在进行的开发.
- 讨论ADC治疗中的挑战和新兴策略.
主要成果:
- 多种ADC已经证明有效,并获得了对乳腺癌的监管批准.
- 目前正在进行的临床试验显示了许多ADC的有希望的结果.
- 通过组合疗法和下一代ADC设计,正积极应对耐药性和毒性等关键挑战.
结论:
- 更深入地了解ADC的设计和开发对于推进癌症治疗至关重要.
- 未来的研究应该专注于克服耐药性,减轻毒性和识别预测生物标志物.
- 在ADC技术的持续创新有望进一步改善瘤治疗结果.
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
01:31Hybridoma Technology
13.9K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
13.9K
01:30Cancer Vaccines
313
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
313